Can a Serum Metabolomic Fingerprint Prove Cannabis Impairment? A 35-Person Placebo-Controlled Study

Short answer: Not yet. A controlled human experiment identified differences in endogenous serum metabolites between occasional and chronic cannabis users and found metabolic changes associated with a laboratory attention task after THC. But its roughly 80% classification result concerned prior cannabis-use frequency, not proof that an individual was impaired. No validated one-sample forensic impairment classifier, driving outcome, or legal threshold was established.

Madrid-Gambin and colleagues studied 35 cannabis users who received vaporized THC and placebo on separate days. Occasional users experienced a significant increase in lapses during a psychomotor vigilance task after THC; chronic users did not show the same significant average change. Meanwhile, both groups reported feeling more intoxicated after THC. Serum metabolomic patterns differed between the groups before dosing and responded differently during the following 70 minutes. The relevant original experiment is Madrid-Gambin et al., Neuropsychopharmacology (2025).

The forensic distinction: exposure history, acute effects, and case-specific impairment

A biological classifier can answer several fundamentally different questions. It might separate people with different patterns of past cannabis use; identify a recent change after administration; correlate with a particular laboratory reaction-time measure; or predict unsafe performance by a specific individual. These are not interchangeable accomplishments. In this study, the approximately 80% model was trained to distinguish chronic from occasional users from baseline metabolites. It was not a classifier of impaired versus unimpaired drivers.

The second component of the research compared an individual’s post-treatment metabolic changes with their own placebo and predose reference. That is valuable experimental control, but a real traffic stop or workplace investigation seldom supplies the same person’s pre-exposure serum metabolome, standardized prior placebo session, and repeated timed samples. The study explicitly identified future single-sample validation as unfinished work.

Who participated—and how often was each person tested?

The investigators recruited 35 healthy adults, average age 22.0 years (standard deviation 2.2): 18 occasional users and 17 chronic users. Occasional use meant up to three times per week over the preceding year. Chronic use meant at least four times weekly. These groups were defined by history, not by a separate laboratory diagnostic standard of physiological tolerance.

Each participant took part in two double-blind test sessions, receiving active cannabis on one day and cannabis placebo on another, with treatment order counterbalanced and a minimum seven-day washout. Thus, the two sessions and five serum sampling times created repeated observations on the same 35 people, not 70 or hundreds of statistically independent subjects. The analysis accounted for within-person measurements using repeated-measures methods.

Entry restrictions excluded major relevant medical conditions and certain medications. That makes acute laboratory signals easier to study but narrows the range of patients, drug combinations, chronic illnesses, and uncontrolled driving circumstances to which the results can be extrapolated. The sample was also too small to estimate rare error rates for courtroom use.

What was administered, and what was directly measured?

Active sessions used vaporized Bedrobinol cannabis standardized to an administered target of 300 micrograms THC per kilogram body weight; placebo sessions used cannabis placebo. The product was reported as 13.5% THC. An administered weight-based target is not the same as actual absorbed systemic dose, and this study did not derive a universally transferable blood concentration from it.

Venous specimens were obtained and processed for serum analysis. The targeted LC–MS/MS metabolomics platform quantified 91 candidate endogenous biomarkers and 22 ratios representing several pathways, including organic acids, lipids, aromatic amino acids, and endocannabinoid-related compounds. Sample times were immediately before treatment and 10, 30, 50, and 70 minutes afterward. Samples were aliquoted and stored frozen. Cannabinoid determinations were also made under methods described in the primary research.

Serum is a processed blood-derived specimen and is not equivalent to an unprocessed forensic venous whole-blood sample. Concentrations expressed as serum ng/mL cannot simply be relabeled whole-blood THC concentrations. There were no trial measurements of driver breath cannabis concentration, urine metabolite screening, oral-fluid roadside devices, hair concentration, or vitreous humor. For more on compartment-specific interpretation, see the site’s biological matrices guide.

How did the investigators measure attention and perceived intoxication?

A six-minute psychomotor vigilance task (PVT) measured reaction to visual stimuli. The specified endpoint was the count of attentional lapses, defined as reaction time exceeding 500 milliseconds. The laboratory task was administered about 10 and 30 minutes after treatment. Participants separately rated how high they felt, using a 0–10 visual scale, at approximately 20 and 40 minutes.

These are two distinct outcomes. The PVT provides a controlled behavioral measure of sustained attention. A self-reported high rating measures the person’s subjective experience. Neither is a complete functional assessment of car control, hazard detection, lane maintenance, divided attention, collision avoidance, or the ability to give accurate eyewitness testimony. A metabolite associated with one endpoint cannot be treated as a validated proxy for all the others.

What did direct serum THC testing show?

Mean serum THC concentrations at 10 and 30 minutes after active vaporization were 9.69 and 3.41 ng/mL in occasional users and 17.10 and 7.63 ng/mL in chronic users, respectively. The published standard deviations were 6.01 and 2.03 ng/mL for the occasional group and 14.2 and 4.66 ng/mL for the chronic group. These are group means from specific timed serum samples, not fixed boundaries dividing impaired and unimpaired people.

Before the experimental dose, chronic users had residual mean serum THC of 2.99 ng/mL (SD 2.42), while the occasional group was negative at baseline under the study’s screening conditions. Importantly, the investigators administered test sessions to chronic participants who screened THC-positive at baseline, while occasional users had to pass a negative drug screen. That difference reflects the design and use histories and should not be flattened into a common zero baseline.

A higher group mean THC concentration at a given time did not produce a larger statistically significant PVT effect in chronic users. This disconnect is one reason individual performance cannot be read directly from a numerical serum THC result. It is not evidence that any particular chronic user was necessarily unimpaired, nor that every occasional user failed the attention task.

Which baseline metabolites separated frequent from less-frequent users?

At the baseline assessment, while neither group was being experimentally intoxicated, the investigators used repeated double cross-validated partial least-squares discriminant analysis to select 14 endogenous metabolites. Their model classified use-frequency groups at about 80% accuracy in the study, with a 200-iteration permutation analysis reported at p < .01. The classification target was study-group membership based on use history. It was not independent validation against a forensic standard for drug impairment.

Lower chronic-user concentrations were reported for tyrosine, phenylalanine, kynurenine and kynurenic acid; branched-chain amino acids such as valine and leucine; and 2-arachidonoylglycerol (2-AG) and 2-oleoylglycerol (2-OG). A selected ceramide and hexanoic acid were higher in the chronic group. Because the metabolites were selected in a multivariate model, the table of group means cannot be substituted for prospectively validated individual diagnostic decision limits.

Selected primary baseline serum values

The full study Table 1 reports all 14 selected compounds. The selected subset above preserves the original means, standard deviations, and biological units but does not claim that each displayed row independently met a validated clinical threshold. Even excellent separation inside a small research sample needs external validation, prespecified cutoffs, error estimates, and demonstration that unrelated influences do not generate the same pattern.

What changed after active cannabis compared with placebo?

In the occasional-use group, multiple organic acids and energy-related metabolites increased after active vaporization relative to placebo, after the authors’ hierarchical multiple-comparison correction. The reported significant series included beta-hydroxybutyrate (W=7.44; p=.033), lactate (6.44; .033), malate (5.14; .047), succinate (4.87; .047), isocitrate (4.69; .047), glutarate (7.41; .033), alpha-hydroxybutyrate (6.43; .040), and alpha-hydroxyglutarate (5.73; .047). These shifts suggest a metabolic response under the study conditions, not a direct serum measurement of motor impairment.

Reductions in palmitoylethanolamine and docosatetraenoylethanolamide were described as trends but did not survive false-discovery-rate correction. A trend that loses statistical significance after adjustment should not be promoted as confirmed evidence merely because its biological interpretation sounds plausible.

In the chronic-use group, fewer acute metabolite changes cleared the correction threshold. Isoleucine (W=9.90, p=.038), leucine (7.87, .039), and tyrosine (8.13, .039) increased relative to placebo, particularly at the later 50–70-minute sampling times. Changes in cortexolone and beta-hydroxybutyrate in this group failed the study’s adjusted significance standard. An increase in one amino acid group is not a direct measure of clinical recovery or tolerance at a traffic stop.

What happened to attention and subjective high?

Occasional users had a statistically significant PVT treatment effect (F(1,31.66)=5.338, p=.028) and time effect (F(1,38.35)=7.351, p=.010). The average number of attentional lapses rose under cannabis. The same treatment-related average PVT increase was not statistically significant in chronic users. The experiment did not establish absence of risk for every chronic individual or every cognitive domain.

Subjective intoxication moved differently. Both groups reported significantly greater high ratings after active THC: occasional-user treatment F(1,34.79)=72.63, p<.001; chronic-user treatment F(1,35.61)=35.61, p<.001. Time effects were significant in both groups. Thus, an average self-report of feeling high can increase even when a chosen sustained-attention endpoint does not show a significant mean response within a small subgroup.

Did any metabolite track changes in vigilance?

The researchers associated each participant’s cannabis-minus-placebo PVT change with their corresponding metabolite change, including age, sex, and baseline THC among the evaluated predictors. In occasional users, changes in certain hexosylceramides, ceramides, and lysophosphatidylcholines were associated with lapses about 10 minutes after cannabis, with some lipid associations persisting around 30 minutes. These relationships were derived from the observed experimental range, using the study’s statistical selection approach.

Among chronic users, 2-linoleoylglycerol (2-LG) was the limited metabolite association with lapse changes at 10 minutes; none met the specified criterion at 30 minutes. It would therefore be misleading to write that one universal lipid predicts cannabis impairment equivalently across both use-frequency groups.

Association alone does not establish the metabolite caused the attentional lapse. Both could reflect the same upstream process, variation in THC exposure, nutrition, baseline physiology, or another factor. The research did not prospectively test a prespecified biomarker threshold on unseen drivers to measure sensitivity, specificity, positive predictive value, or courtroom-relevant false classification.

What about metabolomic associations with feeling high?

For occasional users, some lipid changes were associated with subjective-high differences at 20 minutes, including selected hexosylceramides and lysophosphatidylcholines. No significant metabolite associations remained for their subjective rating at 40 minutes. For chronic users, the paper reported limited associations, with LPC 16:0 as an exception. This time-specific, group-specific behavior cautions against describing the fingerprints as stable personalized intoxication meters.

Feeling high is itself not binary: a participant can report a noticeable subjective experience with little change in a particular group-averaged vigilance result, or perform worse on a task without reporting a corresponding intensity. A biomarker model must be validated against the exact outcome it is purported to predict. A history classifier, subjective-rating correlation, and an individual impairment decision are three different models with three different reference standards.

Why an 80% classifier is not an 80%-accurate DUI test

The repeated double cross-validation and permutation analysis offer evidence that the baseline metabolites contained signal about the study’s frequency-of-use category. Their classification figure includes uncertainty, and the research consisted of only 18 occasional and 17 chronic users. No external police or medical cohort independently confirmed equivalent performance, and no prospective field cutoff for any metabolite panel was established.

The model classified people according to an assigned frequency category that was known from self-report, not a blinded adjudication of intoxication or unsafe function. An 80% score against use history could coexist with much lower, higher, or unknown accuracy for identifying people whose driving was demonstrably impaired. That latter question was not tested, so no percentage can responsibly be supplied.

In forensic reporting, predictive value depends not just on analytic association but also on the prevalence of the outcome, calibration, validation population, and balance of false positives and false negatives. Without such data, it is impossible to calculate the probability that a particular motorist was impaired from one serum metabolomic profile. For foundational distinctions between identification and interpretation, see the site’s confirmatory drug testing guide.

Why the specimen and sampling schedule matter in a case

The study’s metabolic signatures were obtained from processed serum under controlled research sampling. For a real forensic laboratory, specimen preparation, time to processing, storage, assay validation and quality-control acceptance would need to be documented for each proposed endogenous compound. Many endogenous molecules respond to ordinary physiological conditions unrelated to cannabis. Their concentration cannot automatically be imported from serum into legally defined whole blood.

The timing problem is equally important. Five serum sampling occasions over 70 minutes, plus known predose samples and placebo visits, made it possible to calculate individual change scores. A one-time postincident blood draw lacks that reference. The investigators themselves proposed future validation of a single-sample model or collection of a non-intoxicated personal baseline. Neither clinical workflow was validated here.

Moreover, pre-dose chronic-user THC positivity was allowed by the design while occasional participants needed a negative pretest. This is relevant to interpreting group differences and illustrates why cannabinoid positivity by itself cannot serve as an experimentally validated impairment label. A concentration-time curve also does not authorize back-calculating an exact consumption time or absorbed THC dose for a particular person. See the site’s pharmacokinetics interpretation guide.

Important analytical and statistical limitations

The authors used a targeted rather than whole-unknown-metabolome platform. Their 91 metabolite measurements and 22 ratios were processed through specified normalization, missing-data and model-selection procedures. Although a hierarchical correction for multiple testing was applied to time-dependent associations, the large number of related predictors and relatively small group sizes still warrant independent replication. The published supporting tables containing all individual model outputs should be consulted before asserting unreported per-marker confidence intervals or cutoffs.

Likewise, the model’s cross-validation is not equivalent to deployment validation in a new population. Calibration can shift with demographics, medications, fasting state, other substances, medical conditions, storage, and laboratory platform. The participants were young, medically screened volunteers, not a cross-section of clinical patients or motorists with uncertain exposure histories. A marker that separates frequency groups in this design could perform differently in another setting.

A further inference limit lies in the choice of the PVT endpoint. Sustained attention is relevant to safety-sensitive activities but represents only one component of complex performance. The study did not measure actual steering, peripheral hazard detection, law-enforcement observations, collision rates, field sobriety evaluations, clinical diagnosis, or eyewitness truthfulness. Its significant PVT group result should be reported as an experimental attention effect—not converted into those unmeasured outcomes.

What a forensic expert can responsibly say

The strongest defensible conclusion is that endogenous serum metabolomics responded to an experimentally controlled cannabis challenge and differed by prior use frequency in 35 participants. Several corrected metabolite changes and laboratory task effects supported that observation, while several putative changes did not survive multiplicity correction. The accompanying THC measurements show why a chemical concentration and a chosen behavioral endpoint require independent interpretation.

It would exceed the research to assert that a ceramide, beta-hydroxybutyrate, 2-AG value or combined fingerprint diagnoses individual intoxication, measures legal impairment, identifies when cannabis was consumed, or proves a crash or eyewitness error. Validated assay performance, an independently calibrated threshold, the case’s biological matrix, repeated and confounding exposures, and direct functional evidence would all be necessary to move toward those questions.

The complete experiment, tables and full discussion can be read in the original primary research publication. That primary report—not an abstract, headline, or extrapolated individual cutoff—is the appropriate basis for evaluating the strength and scope of the finding.

Frequently asked questions

1. Can metabolomics currently prove an individual was impaired by cannabis?

No. This 35-person study demonstrated group-level associations under a placebo-controlled protocol, but did not validate an individual, field-ready serum-metabolomic diagnostic test with predetermined error rates or a legal impairment cutoff.

2. Does 80% accuracy mean the metabolomic panel detects intoxicated drivers correctly 80% of the time?

No. The model separated chronic from occasional users at baseline according to prior frequency of use. It did not classify independently confirmed impaired versus unimpaired drivers. The outcomes and reference labels are different.

3. Did the investigators directly measure THC in blood?

They reported measured cannabinoid concentrations from collected blood-derived serum, including timed THC means. That does not make the result interchangeable with an unprocessed forensic venous whole-blood THC concentration, and a serum THC value was not validated as an impairment threshold.

4. Why were chronic users’ PVT changes less evident even with higher mean serum THC?

The study found no statistically significant average PVT lapse increase in its chronic group while occasional users showed a treatment effect. Prior exposure and tolerance are plausible explanations discussed by the investigators, but the study cannot establish that any individual chronic user was unaffected or safe to drive.

5. Was beta-hydroxybutyrate a validated cannabis impairment biomarker?

No. It increased significantly after active THC relative to placebo in occasional users under the research protocol, with an FDR-adjusted p=.033. No prospective person-level diagnostic decision boundary, independent clinical validation, or specificity against other causes of metabolic change was demonstrated.

6. Did the experiment test the accuracy of eyewitness testimony or real-world driving?

No. It used a psychomotor vigilance reaction-time task and subjective-high ratings. Driving behavior, traffic collisions, scene observations and eyewitness accuracy were not measured, so no individual case finding can be inferred from these endpoints alone.

7. What would be required before a serum metabolomic panel could be offered as forensic evidence of impairment?

At minimum, a prespecified assay and reference intervals, robust specimen and handling validation, independent external populations, quantified false-positive and false-negative rates, controls for concurrent illness and other drugs, temporal validation from a single specimen, and demonstration against a relevant objective functional endpoint rather than merely use history.